Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06NAG
|
|||
| Former ID |
DNCL002305
|
|||
| Drug Name |
Anti-CD137
|
|||
| Synonyms |
BMS-663513
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Co-stimulatory molecule 4-1BB (CD137) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathway Interaction Database | Downstream signaling in naï | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00612664) Phase II, 2nd Line Melanoma - RAND Monotherapy. U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.